Buy PYPD by Oct 22, 2026.

PolyPid ($PYPD) just locked in a major exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada (prevention of surgical site infections). Key terms: * $15M upfront at signing * Another $15M upon expected FDA acceptance of the NDA (targeted for August 2026) * Up to \~$300M more in regulatory, development, and sales milestones * Tiered royalties mid-teens to mid-twenties % * PolyPid keeps manufacturing rights worldwide + all rights outside U.S./Canada + full ownership of the …